Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Verona Pharma has started a Phase II trial of its respiratory drug RPL554 to determine if the drug has sustained bronchodilator actions, and is safe when given daily to patients who are suffering from mild asthma.
Subscribe to our email newsletter
The company has also treated first patient in the trial.
The RPL554 compound is a new bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed phosphodiesterase (PDE) 3/4 inhibitor.
The previous trials has established the efficacy of the drug.
The key measurement that will be performed in the trial is the standard measure of FEV1 (Forced Expiratory Volume in 1 sec) to test the effect of RPL554 on lung function.
Verona Pharma CEO Michael Walker said this trial, which has just started, will test the therapeutic usefulness of RPL554 when given over a period of days, reflecting the manner in which the drug will eventually be used medically.
"While licensing efforts for RPL554 continue, the Company is performing further clinical trials to broaden its knowledge of the therapeutic utility of RPL554 and, of course, add value in terms of licensing," Walker said.